Navigation Links
Mylan Acquisition of Agila Receives Approval from India's Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
Date:9/3/2013

latory proceedings, actions or changes; general market perception of the transaction; uncertainties and matters beyond the control of management; the ability of the company to achieve the synergies or other benefits anticipated as a result of the acquisition; any conditions imposed upon the company in connection with obtaining regulatory approvals; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
2. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
3. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
4. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
5. Roger Graham Named President of Mylan Specialty
6. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
7. Mylan to Speak at the Goldman Sachs 34th Annual Global Healthcare Conference
8. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
9. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
10. Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy
11. Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015  Egalet Corporation (Nasdaq: EGLT ) ... on developing, manufacturing and marketing innovative pain treatments, ... $60.0 million aggregate principal amount of its convertible ... private placement to qualified institutional buyers pursuant to ... as amended (the "Act"). Egalet also granted the ...
(Date:4/1/2015)... April 1, 2015  Salix Pharmaceuticals, Ltd. ("Salix"), ... Inc. (NYSE: VRX ) (TSX:VRX), today announced ... $750,000,000 aggregate principal amount of its 6.00% Senior ... " Notes ") pursuant to two redemptions. On ... principal amount of the Notes, and on May ...
(Date:4/1/2015)... AVIV, Israel , April 1, 2015 /PRNewswire/ ... a clinical-stage biopharmaceutical company focused on the development ... the treatment of liver diseases and cholesterol gallstones, ... Tonelli as Vice President of Clinical Operations. ... progressive experience in clinical operations, development and regulatory ...
Breaking Medicine Technology:Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 7Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 2Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 3Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 2Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 3
... blood ... flow, muscle oxygen supply, HOBOKEN, N.J., Oct. 17 ... reveals Pycnogenol(R),(pic-noj-en-all), an antioxidant plant extract from the bark of the ... which leads to an increase in blood flow and oxygen supply,to ...
... vs. Drug-Eluting and Bare ... ... TRIAS (TRI-stent Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered R stent has ... to Robbert de Winter, M.D., Ph.D.,principal investigator and director of the ...
Cached Medicine Technology:New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 2New Study: Pine Bark Extract Boosts Nitric Oxide (NO) Production 3Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2
(Date:4/1/2015)... (PRWEB) April 01, 2015 IQ Formulations ... health and nutritional supplement companies in the U.S., today is ... testing and quality control standards for its herbal supplements.* GNC ... supply chain to ensure the accuracy of labeling on its ... veteran and IQ Formulations CEO Jay Cohen said: ...
(Date:4/1/2015)... Sheboygan, WI (PRWEB) April 01, 2015 ... or dryness occur, waiting days or weeks for an ... wants. Historically same and next day appointments haven’t been ... Falls area, Forefront Dermatology’s offices have noticed demand for ... , “We realize how important relief or answers ...
(Date:4/1/2015)... The 2015 Deep Market Research ... professional and in-depth study on the current state ... with a focus on the Chinese situation. , ... are Pfizer, Lek Pharmaceuticals D.D., Dr Reddys Labs ... Limited, Cadila Healthcare Limited, Sandoz Inc, Teva Pharms, ...
(Date:4/1/2015)... The U.S. Department of Health and Human ... who are waiting for a lifesaving organ transplant.” Many ... , In the “Play Through with Erik ... TOUR golfer and two-time heart transplant recipient, raises awareness ... donors. He inspires viewers by reminding them, "You ...
(Date:4/1/2015)... 01, 2015 Natural fertility experts from ... attend the world’s first Integrative Fertility Symposium ( https://ifsymposium.com/ ... Centre (SFU Downtown Campus), 515 West Hastings Street, Vancouver ... Sunday, May 3rd, 3:00 pm to 5:00 pm at ... first of its kind in the world to bring ...
Breaking Medicine News(10 mins):Health News:IQ Formulations Applauds GNC for Enhancing Its Testing and Quality Control Processes for Herbal Supplements 2Health News:Dermatology Associates of Wisconsin and Forefront Dermatology Answers Patients' Needs With Unmatched Availability In Sheboygan and Sheboygan Falls 2Health News:Atorvastatin Calcium Industry International & China Market Analysis 2015-2020 2Health News:Atorvastatin Calcium Industry International & China Market Analysis 2015-2020 3Health News:Donate Life America and Genentech have Partnered to Develop the “Play Through with Erik Compton to Donate Life" Public Service Announcement 2Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 2Health News:Vancouver Hosts the World's First Integrative Fertility Symposium 3
... PHILADELPHIA, July 16 On Wednesday, July 22nd, GlaxoSmithKline ... financial results for the three months ended June 30, 2009. ... London Stock Exchange at approximately 7:00 AM EDT . ... Witty, Chief Executive Officer, Julian Heslop, Chief Financial Officer and Moncef ...
... , CAMBRIDGE, Mass., July 16 Biopure ... filed a voluntary petition for relief under Chapter 11 of the ... the District of Massachusetts. Biopure will continue to manage and ... case, subject to the supervision of the Bankruptcy Court. , ...
... ... just launched on Monday. , ... (Vocus) July 16, 2009 -- The National Practice Transition Network (NPTN), created ... practice sales and appraisals, is the first membership-based, commission-free organization to offer such a menu ...
... WASHINGTON, July 16 The American Society of Hematology (ASH) announces ... awarded at ASH,s annual meeting in December. The inaugural recipients are ... of the University of California - San Francisco. , ... named for the late Dr. Ernest Beutler, past president of ASH ...
... , , DETROIT, July ... companies are looking for alternative options to decrease spending without losing ... quality of coverage for their employees and lower their costs by ... Arrangements (HRA). , , ...
... , SANTA CLARA, Calif., July ... reduction was featured recently in the New York Times Fashion ... of Dermatology New York University Medical Center and Founding Director, ... Dr. Kauvar described the LightSheer Duet as a welcome relief ...
Cached Medicine News:Health News:National Practice Transition Network Launches as the Country's First Membership-Based, Commission-Free Dental Practice Transition Company 2Health News:The American Society of Hematology Announces New Honorific Award 2Health News:How To Reduce Cost Without Sacrificing Your Health Coverage 2Health News:Lumenis' High Speed LightSheer(R) Duet(TM) Featured in New York Times Fashion & Style for Eliminating 'Pain and Nuisance' of Hair Removal for Men 2Health News:Lumenis' High Speed LightSheer(R) Duet(TM) Featured in New York Times Fashion & Style for Eliminating 'Pain and Nuisance' of Hair Removal for Men 3Health News:Lumenis' High Speed LightSheer(R) Duet(TM) Featured in New York Times Fashion & Style for Eliminating 'Pain and Nuisance' of Hair Removal for Men 4Health News:Lumenis' High Speed LightSheer(R) Duet(TM) Featured in New York Times Fashion & Style for Eliminating 'Pain and Nuisance' of Hair Removal for Men 5
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of CRP in serum....
For the quantitative in vitro determination of Uric Acid in serum, plasma and urine...
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
For the quantitative in vitro determination of Urea in serum, plasma and urine....
Medicine Products: